A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain

Journal of Clinical Psychopharmacology

Volumn 32, Issue 2, 2012, Pages 165-172

  McElroy, Susan L ^a,b   Winstanley, Erin ^a,b   Mori, Nicole ^a,b   Martens, Brian ^a,b   McCoy, Jessica ^a   Moeller, Dianna ^a   Guerdjikova, Anna I ^a,b   Keck, Paul E ^a,b  

^a Research Institute   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Olanzapine; Weight gain; Zonisamide

Indexed keywords

FLUOXETINE; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; TRIACYLGLYCEROL; ZONISAMIDE;

ADULT; ARTICLE; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BODY MASS; CHLORIDE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COGNITIVE DEFECT; CONCENTRATION LOSS; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EATING HABIT; EOSINOPHIL COUNT; EVENING DOSAGE; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; INCREASED APPETITE; INSULIN BLOOD LEVEL; IRRITABILITY; LEG EDEMA; MALE; OUTCOME ASSESSMENT; PARALLEL DESIGN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; THIRST; TREATMENT DURATION; TREATMENT REFUSAL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT CONTROL; WEIGHT GAIN; XEROSTOMIA;

EID: 84857856190     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182488758     Document Type: Article

References (40)

1. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686-1696. (Pubitemid 29517559)
2. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007;68(suppl 1):20-27.
3. Lipkovich I, Jacobson JG, Caldwell C, et al. Early predictors of weight gain risk during treatment with olanzapine: analysis of pooled data from 58 clinical trials. Psychopharmacol Bull. 2009;42(4):23-39.
4. Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C, et al. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry. 2008;193(2):101-107.
5. Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology. 2010;35(7):1520-1530.
6. Narula PK, Rehan HS, Unni KE, et al. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophr Res. 2010;118(1-3):218-223.
7. Henderson DC, Fan X, Copeland PM, et al. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol. 2009;29(2):165-169.
8. FDA. Meridia (sibutramine): MarketWithdrawal Due to Risk of Serious Cardiovascular Events. October 8, 2010. Available at: http://www.fda.gov/Drugs/ DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ ucm228830.htm. Accessed June 28, 2011.
9. FDA. FDA Announces Withdrawal Fenfluramine and Dexfenfluramine (Fen-Phen). September 15, 1997. Available at: http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ ucm179871.htm. Accessed June 28, 2011.
10. Kothare SV, Kaleyias J. Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008;4(4):493-506. (Pubitemid 351728521)
11. Schwartz MW, Woods SC, Porte D Jr, et al. Central nervous system control of food intake. Nature. 2000;404(6778):661-671. (Pubitemid 30205071)
12. Stanley BG, Willett VL 3rd, Donias HW, et al. Lateral hypothalamic NMDA receptors and glutamate as physiological mediators of eating and weight control. Am J Physiol. 1996;270(2 Pt 2):R443-R449.
13. Supuran CT, Di Fiore A, De Simone G. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008;13(2):383-392. (Pubitemid 351957352)
14. Wallingford NM, Sinnayah P, Bymaster FP, et al. Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats. Neuropsychopharmacology. 2008;33(12):2922-2933.
15. Gadde KM, Franciscy DM, Wagner HR 2nd, et al. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA. 2003;289(14):1820-1825. (Pubitemid 37430252)
16. McElroy SL, Kotwal R, Guerdjikova AI, et al. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry. 2006;67(12):1897-1906. (Pubitemid 46055195)
17. McElroy SL, Suppes T, Keck PE Jr, et al. Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial. J Clin Psychiatry. 2005;66(5):617-624. (Pubitemid 40733705)
18. Hoffmann VP, Case M, Jacobson JG. Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study. J Clin Psychiatry. 2011;17. [E-pub ahead of print].
19. Davoodi N, Kalinichev M, Korneev SA, et al. Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine. Psychopharmacology (Berl). 2009;203(4):693-702.
20. Theisen FM, Linden A, Konig IR, et al. Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine. J Neural Transm. 2003;110(1):111-121. (Pubitemid 36135558)
21. Kluge M, Schuld A, Himmerich H, et al. Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study. J Clin Psychopharmacol. 2007;27(6):662-666. (Pubitemid 351339453)
22. McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry. 2003;160(2):255-261. (Pubitemid 41110450)
23. Wilfley DE, Crow SJ, Hudson JI, et al. Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study. Am J Psychiatry. 2008;165(1):51-58. (Pubitemid 351704552)
24. Hoffmann VP, Ahl J, Meyers A, et al. Wellness intervention for patients with serious and persistent mental illness. J Clin Psychiatry. 2005;66(12):1576-1579. (Pubitemid 43068698)
25. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition with Psychotic Screen (SCID-I/P W/PSY SCREEN). New York, NY: Biometric Research; New York State Psychiatric Institute; 2002.
26. Guy W. ECDEU Assessment Manual for Psychopharmacology, U.S. Department of Health, Education, and Welfare Publication (ADM). Rockville, MD: National Institute of Mental Health, Psychopharmacology Research Branch; 1976 (revision).
27. Kay SR, Fiszbein A, Lindenmayer JP, et al. Positive and negative syndromes in schizophrenia as a function of chronicity. Acta Psychiatr Scand. 1986;74(5):507-518. (Pubitemid 17196675)
28. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-435. (Pubitemid 9006756)
29. Rush AJ, Gullion CM, Basco MR, et al. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med. 1996;26(3):477-486. (Pubitemid 26142491)
30. Gormally J, Black S, Daston S, et al. The assessment of binge eating severity among obese persons. Addict Behav. 1982;7(1):47-55. (Pubitemid 12131037)
31. Stunkard A, Messick S. Eating Inventory Manual. San Antonio, TX: The Psychological Corporation, Harcourt Brace & Company; 1988.
32. White MA, Whisenhunt BL, Williamson DA, et al. Development and validation of the food-craving inventory. Obes Res. 2002;10(2): 107-114. (Pubitemid 135687498)
33. Allison KC, Lundgren JD, O'Reardon JP, et al. The Night Eating Questionnaire (NEQ): psychometric properties of a measure of severity of the night eating syndrome. Eat Behav. 2008;9(1):62-72. (Pubitemid 350303558)
34. Masheb RM, Grilo CM. Emotional overeating and its associations with eating disorder psychopathology among overweight patients with binge eating disorder. Int J Eat Disord. 2006;39(2):141-146. (Pubitemid 43201602)
35. Opgen-Rhein C, Brandl EJ, Muller DJ, et al. Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample. Pharmacogenomics. 2010;11(6):773-780.
36. Muller DJ, Zai CC, Sicard M, et al. Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. Pharmacogenomics J. 2010;17. [Epub ahead of print].
37. Tan W, Fan H, Yu PH. Induction of subcutaneous adipose proliferation by olanzapine in rodents. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(6):1098-1103.
38. Sonsalla PK, Wong LY, Winnik B, et al. The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010;221(2):329-334.
39. Arana A, Wentworth CE, Ayuso-Mateos JL, et al. Suicide-related events in patients treated with antiepileptic drugs. N Engl J Med. 2010;363(6):542-551.
40. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67(3):220-229.